Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review.

IF 6.4 1区 医学 Q1 ONCOLOGY British Journal of Cancer Pub Date : 2024-11-03 DOI:10.1038/s41416-024-02887-1
Bishma Jayathilaka, Farah Mian, Fanny Franchini, George Au-Yeung, Maarten IJzerman
{"title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review.","authors":"Bishma Jayathilaka, Farah Mian, Fanny Franchini, George Au-Yeung, Maarten IJzerman","doi":"10.1038/s41416-024-02887-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immune-related adverse events (irAE) induced by immune checkpoint inhibitors (ICI) are a treatment-limiting barrier. There are few large-scale studies that estimate irAE prevalence. This paper presents a systematic review that reports the prevalence of irAE by cancer type and ICI.</p><p><strong>Methods: </strong>A systematic review was undertaken in MEDLINE OVID, EMBASE and Web of Science databases from 2017-2021. A total of 293 studies were identified for analysis and, of these, event rate was calculated for 272 studies, which involved 58,291 patients with irAE among 305,879 total patients on ICI. Event rate was calculated by irAE and ICI type.</p><p><strong>Results: </strong>Mean event rate for general irAE occurrence across any grade was 40.0% (37.3-42.7%) and high grade was 19.7% (15.8-23.7%). Mean event rates for six specific types of irAE are reported. Mean event rate for ICI monotherapy was 29.7% (27.7-33.2%), 45.7% (29.6-61.7%) for ICI combination therapy, and 30.3% (27.3-35.0%) for both ICI monotherapy and combination therapy.</p><p><strong>Conclusion: </strong>This systematic review characterises irAE prevalence across current research that examines irAE risk factors across cancers and ICI. The findings confirms that irAE occurrence is very common in the real-world setting, both high grade and irAE across any grade.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4000,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41416-024-02887-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Immune-related adverse events (irAE) induced by immune checkpoint inhibitors (ICI) are a treatment-limiting barrier. There are few large-scale studies that estimate irAE prevalence. This paper presents a systematic review that reports the prevalence of irAE by cancer type and ICI.

Methods: A systematic review was undertaken in MEDLINE OVID, EMBASE and Web of Science databases from 2017-2021. A total of 293 studies were identified for analysis and, of these, event rate was calculated for 272 studies, which involved 58,291 patients with irAE among 305,879 total patients on ICI. Event rate was calculated by irAE and ICI type.

Results: Mean event rate for general irAE occurrence across any grade was 40.0% (37.3-42.7%) and high grade was 19.7% (15.8-23.7%). Mean event rates for six specific types of irAE are reported. Mean event rate for ICI monotherapy was 29.7% (27.7-33.2%), 45.7% (29.6-61.7%) for ICI combination therapy, and 30.3% (27.3-35.0%) for both ICI monotherapy and combination therapy.

Conclusion: This systematic review characterises irAE prevalence across current research that examines irAE risk factors across cancers and ICI. The findings confirms that irAE occurrence is very common in the real-world setting, both high grade and irAE across any grade.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
免疫检查点抑制剂诱发的免疫相关不良事件的癌症和治疗特异性发生率:系统综述。
背景:免疫检查点抑制剂(ICI)诱发的免疫相关不良事件(irAE)是限制治疗的障碍。目前很少有大规模研究估计irAE的发生率。本文介绍了一项系统性综述,按癌症类型和 ICI 报告了 irAE 的发生率:2017-2021年,在MEDLINE OVID、EMBASE和Web of Science数据库中进行了系统性综述。共确定了 293 项研究进行分析,并计算了其中 272 项研究的事件发生率,这些研究涉及 305879 名 ICI 患者中的 58291 名irAE 患者。事件发生率按虹膜急性缺损性和 ICI 类型进行计算:任何等级一般虹膜AE的平均事件发生率为40.0%(37.3-42.7%),高等级为19.7%(15.8-23.7%)。报告了六种特定类型虹膜睫状体异常的平均事件发生率。ICI单药治疗的平均事件发生率为29.7%(27.7-33.2%),ICI联合治疗的平均事件发生率为45.7%(29.6-61.7%),ICI单药治疗和联合治疗的平均事件发生率均为30.3%(27.3-35.0%):本系统性综述描述了当前研究中虹膜睫状体E发生率的特点,这些研究探讨了不同癌症和 ICI 的虹膜睫状体E风险因素。研究结果证实,虹膜睫状体异常在现实世界中非常常见,包括高级别虹膜睫状体异常和任何级别的虹膜睫状体异常。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
British Journal of Cancer
British Journal of Cancer 医学-肿瘤学
CiteScore
15.10
自引率
1.10%
发文量
383
审稿时长
6 months
期刊介绍: The British Journal of Cancer is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research.It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention,diagnosis and treatment.
期刊最新文献
Cardiotoxicity following thoracic radiotherapy for lung cancer. Low-dose arsenic trioxide inhibits pancreatic stellate cell activation via LOXL3 expression to enhance immunotherapy in pancreatic cancer. Perioperative safety of risk-reducing mastectomy. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1